A Correlative Study of Melanoma Tumor-Infiltrating Lymphocytes (TILs) and Response to Ipilimumab
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- 06 Feb 2018 Status changed from active, no longer recruiting to completed.
- 21 Jun 2016 Planned End Date changed from 1 Oct 2015 to 1 Oct 2017.
- 21 Jun 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2017.